For the seventh year, World BI’s Flagship Clinical Trials Innovation Programme (CTIP) showcased the latest useful solutions and technologies for sustainable clinical development of drugs. The event took place in Boston on May 17 and 18. With an exclusive gathering of high profile professionals, the event’s attendee profile ranged from about 90 to 100 clinical trials specialists with more than 12 hours of networking throughout the course of two days.
Experienced senior level executives from pharma and biotech industries along with contract research organizations converged this year to our unique platform to build long-lasting relationships. This event encourages businesses of all types and sizes to come and meet decision makers like CEOs, directors, vice presidents, as well as departmental heads of the clinical trials sector.
New themed sessions added this year covered recent advancements in the following areas:
- Clinical Trials Operations
- Patient Centricity from Patient’s Point of View
- Disease Specific Clinical Trials including Oncology and Rare Diseases
- Risk Based Monitoring
- Partnerships and Collaborations
- Disruptive Innovations and Future Trends
2017 CTIP chairs and keynote speakers
We had the privilege to work with two top industry experts as our chairpersons:
- Spyros Papapetropoulos; VP, Clinical Transformation at TEVA Pharmaceuticals
- Jeffry B. Lawrence; SVP, Chief Medical officer at LFB Biopharmaceuticals Ltd
Spyros Papapetropoulos kicked off the event on May 17 with the chairperson welcome address. As the day unfolded, attendees listened to informative keynote presentations from the chairman himself, followed by Fernando Venegas (Biogen), Tom Parke (Berry Consultants), Dave Jacob (ThinkGenetics), Dr. Alaa Assem (ClinArt), Irving Sucholeiki (Aquilus Pharmaceuticals) and Gerald Yakatan (IriSys). The first day concluded with an interactive session on partnerships and collaborations chaired by Sudeesh Tantry; VP Clinical development, Glenmark.
Jeffry Lawrence opened the second day of the conference and led the day with interactive keynote plenaries from Elizabeth Beatty (Bristol Myers Squibb), Neil Vivian (OMNICOMM), Dr. Richard Walovitch (WorldCare Clinical) and an engaging tag team presentation by Jeffry B. Lawrence and Kerry B. Biron from LFB Pharmaceuticals about managing the challenges of clinical trials in ultra-rare diseases. CTIP 2017 concluded with a think tank session led by Karthinathan Thangevelu (Sanofi Genzyme) offering lots of key takeaways in the clinical development landscape.
The event program, playing on its strength, had participants engaged through innovative exhibitions, exclusive one-on-one meetings, productive panel discussions, strong agenda with high level speakers and multiple networking opportunities for both our delegates and sponsors.
CTIP’s purpose is to provide a platform where professionals from all over the world gather in a one place and share their ideas and new advancement in the field of pharma and biotech, was met this year with our exceptional two-day gathering in Boston.
Filed Under: Drug Discovery